SGX-Listed Singapore eDevelopment's Global BioLife Inc Develops Breakthrough Modified Sugar
SINGAPORE, Oct, 24 2017 - (ACN Newswire) - SGX-listed Singapore eDevelopment Ltd ("SeD") announced today that U.S. biomedical subsidiary Global BioLife Inc. has developed a breakthrough low-calorie, low glycemic index, natural, modified sugar Laetose -- which has the potential to affect the world's sugar market.
Global Biolife has established a collaboration with top U.S. candy manufacturer Quality Candy Company LLC for the development, manufacture and global distribution of Laetose.
Developed by Mr Daryl L.Thompson, Global BioLife Director of Scientific Initiatives, Laetose is a functional sugar with a 30% to 50% lower calorie-count than regular sugar, possesses low glycemic properties, and also assists in mitigating inflammatory responses.
According to a World Health Organisation report released in Oct '17, the number of obese children aged 5 to 19 rose globally more than ten-fold from 11mil in 1975 to 124mil in 2016. The World Health Organisation report said that countries should seek to reduce consumption of cheap, ultra-processed, calorie-dense nutrition-poor foods.
Studies have shown that excessive sugar consumption is the primary cause of modern diseases such as cardiovascular disease, Type-2 diabetes, metabolic syndrome and obesity. While sugar is not toxic, the human body perceives it as such and, in turn, initiates pro-inflammatory responses. Laetose could help mitigate such reactions by reducing the rate of glucose absorption throughout the body.
Quality Candy has a Safe Quality Food ("SQF") Level 3 - Excellent certified manufacturing facility and is a leading manufacturer and distributer of high-quality candy with distribution in locations across the globe. They will utilize their state-of-the-art facility and expertise to manufacture Laetose according to the unique formula discovered by Global BioLife.
"In this day and age, we should be exploring ways to make smarter foods. Our Laetose modified sugar has been designed specifically for this purpose," said Global BioLife's Mr Thompson, a pioneering natural products scientist cited, amongst others, for his achievements in organic and carbohydrate chemistry.
Mr Chan Heng Fai, Executive Chairman of SeD, said: "Cardiovascular disease, Type-2 diabetes, metabolic syndrome and obesity have become a global epidemic. SeD has invested in Global BioLife as a think tank designed to research and develop smarter consumer products to reverse or mitigate this growing trend."
"Quality Candy has been on a quest for over a decade, looking for a natural sugar substitute," said Mr Jim Gist, Chief Revenue Officer of Quality Candy. "This product is finally the breakthrough our industry needed to improve existing reduced-calorie and sugar-free products and help consumers around the world live a healthier lifestyle."
The market for a safe and affordable alternative to sugar is growing due to increasing awareness of health risks associated with the excessive consumption of refined sugar. Although Laetose is marketed as an alternative usable in everything from baking to cooking, and as a tabletop sweetener, the ultimate goal is to infuse Laetose into the multibillion-dollar beverage industry. Unlike other natural-based and artificial sweeteners widely used in beverages, Laetose's unique patent-pending formula has no aftertaste.
"Due to the perceived toxicity of prolonged use of artificial sweeteners and the inability to use them as a direct replacement for sugar in baking and many beverages, we believe our product will have a direct advantage. We believe that the world is looking for a way to maintain sweetness while avoiding the negative effects of sugar and we intend to provide the solution," Mr Thompson added.
Dr Peggy Tang, Global BioLife CEO, said: "Laetose is our first step in creating smarter foods. We have confidence that our collaboration with industry leader Quality Candy will enable us to accomplish our goal."
About Singapore eDevelopment Ltd (SGX:40V)
Incorporated on 9 Sept 2009 and listed on the SGX in July 2010, Singapore eDevelopment Ltd [SGE.SP; SINE.SP] is involved in property development and investment primarily in the United States and Western Australia; information technology-related businesses; development, research, testing, manufacturing, licensing and distribution of biomedical products; and investment activities. For more information, please visit www.SeD.com.sg or mail : [email protected].
About Global BioLife Inc.
Global BioLife Inc. ("GBLI") is a 80%-held direct subsidiary of Global BioMedical Inc., a wholly-owned direct subsidiary of Singapore BioMedical Pte. Ltd., in turn a wholly-owned direct subsidiary of Singapore eDevelopment Ltd, a company listed on the Singapore Exchange. The remaining shares of Global BioLife Inc. are held by Global Research & Discovery Group Scientific LLC ("GRDGS") and ASX-listed Holista CollTech Ltd with 10% each.
With an aging population and a growing focus in healthcare issues, biomedical science has become increasingly vital. GBLI strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. By tapping into the scientific expertise of GRDGS and Holista, GBLI pledges to undertake a concerted effort in the R&D, drug discovery and development for the prevention, inhibition and treatment of neurological, oncology and immuno-related diseases. GBLI is also collaborating with its partners to develop second generation mosquito defence technologies, which are DEET alternatives, to protect against mosquito transmitted diseases such as Zika and Dengue. For more information, please visit: http://www.globalbiolife.com.
Source: Singapore eDevelopment Ltd
Sectors: BioTech, HealthCare, Cosmetics/Spec.Chem
Copyright ©2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
More Latest Release >>
Honda's Cumulative Worldwide Power Products Production Reaches 150 million Units
Sep 19, 2019 20:20 JST
Eisai to Present Latest Data on Lemborexant at World Sleep Congress
Sep 19, 2019 20:06 JST
Toyota to Invest R$1 Billion in its Plant in Brazil to Produce New Vehicle
Sep 19, 2019 14:11 JST
Fujitsu Launches IoT Measuring device for more efficient measurements in the Apparel Industry
Sep 19, 2019 11:41 JST
Eisai Selected for Membership in Dow Jones Sustainability Asia Pacific Index 2019
Sep 18, 2019 21:40 JST
Mitsubishi Motors Hosts World Debuts of Small Electric SUV Concept Car at 46th Tokyo Motor Show 2019
Sep 18, 2019 21:31 JST
KDDI Joins Merpay, LINE Pay, and NTT DOCOMO's Merchant Alliance "Mobile Payment Alliance (MoPA)"
Sep 18, 2019 21:19 JST
DOCOMO to Commence Deployment of World's First 4G/5G Multi-vendor Radio Access Network Conforming to O-RAN Specifications
Sep 18, 2019 15:12 JST
FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma
Sep 18, 2019 14:58 JST
MHI-MME to Take Over Production of MET Turbochargers
Sep 18, 2019 14:46 JST
KAHRAMAA, QEWC and MHPS Sign MOU on Internship Program for Young Qatari Engineers
Sep 18, 2019 14:41 JST
Toyota Installs Stationary Fuel Cell Generator Based on the Mirai FC System at its Honsha Plant in Japan
Sep 18, 2019 13:34 JST
Fujitsu Develops Digitization Technology to Quantify Various Walking Characteristics Resulting from Diseases
Sep 18, 2019 11:30 JST
Toyota Injects $391 Million New Investment in its San Antonio Assembly Plant
Sep 18, 2019 07:54 JST
Hitachi to Integrate Hitachi Vantara and Hitachi Consulting to Accelerate Global Expansion of Hitachi's Social Innovation Business and Digital Growth
Sep 18, 2019 07:42 JST
Eisai Receives IIA Japan Chairman's Award of Institute of Internal Auditors - Japan
Sep 17, 2019 16:42 JST
Toyota Rolls Out Completely Redesigned Corolla, Corolla Touring, and Unveils Improvements to the Corolla Sport in Japan
Sep 17, 2019 13:16 JST
A Power Stage Win and Crucial Points for TOYOTA GAZOO Racing
Sep 17, 2019 09:10 JST
MHI Included in Dow Jones Sustainability Asia Pacific Index for Third Consecutive Year
Sep 17, 2019 01:00 JST
Mitsubishi Motors to Begin Producing the XPANDER in Vietnam in 2020
Sep 16, 2019 09:05 JST